摘要
目的 评价吲哒帕胺 1 5mg新型缓释片 (SRI .D)的长效降压疗效及安全性。方法 2 4例轻中度原发性高血压患者 ,服SRI .D 1 5mg前和 8周后分别进行连续 3 0小时的动态血压监测 ,并测定血钾及血尿酸 ,观察药物的安全性。结果 服药后诊所血压总有效率 54 2 %。SBP/DBP由治疗前的 (14 2 4± 11 9/ 97 2± 5 0 )mmHg降至治疗后的(13 2 5± 8 4/ 88 0± 6 0 )mmHg ,心率无明显改变。前 2 4小时ABPM血压由 (13 0 3± 9 1/ 86 3± 6 3 )mmHg降至 (12 3 4±10 3 / 81 4± 7 3 )mmHg ,延长段 6小时ABPM血压由 (13 6 9± 9 7/ 90 7± 6 0 )mmHg降至 (12 8 0± 8 6/ 85 7± 7 9)mmHg ,两者均有显著意义。SBP和DBP的T/P比值分别为 0 75和 0 73。治疗后血钾由 (4 6± 0 56)mmol/L下降至 (4 1±0 3 6)mmol/L(P <0 0 1) ,最低值为 3 5mmol/L(2例 )。血尿酸值由服药前的 (3 3 3 8± 73 0 )mol/L变为 (3 67 9± 88 3 )μmol/L ,异常的例数由 3例上升至 7例 ,但尚无统计学差异。 结论 吲哒帕胺 1 5mg缓释片每日 1次给药降压平稳而达 3 0小时以上 。
Objective To evaluate the effects and safety of sustained released indapamide(SR I.D) on patients with mild-to-moderate essential hypertension. Methods All patients(24 cases) received (SR I D)1 5 mg once daily for 8 weeks. Ambulatory blood pressure monitoring was carried out for 30 hours continuously before and after the treatment. Serum potassium and uric acid were measured. Results The total response rate was 54 2%. BP decreased significantly from (142 4±11 9/97 2±5 0)mmHg to(132 5±8 4/88 0±6 0)mmHg. No change in heart rate was found. The average blood pressure(ABPM) decreased from (130 3±9 1/86 3±6 3)mmHg to(123 4±10 3/81 4±7 3)mmHg in the early 24 hours and from (136 9±9 7/90 7±6 0)mmHg to(128 0±8 6/85 7±7 9)mmHg in the later 6 hours. The T/P ratios were 0 75 and 0 73 for SBP and DBP respectively. Serum potassium was decreased from (4 6±0 56)mmol/L to(4 1 ±0 36)mmol/L(P<0 01), with the lowest value being 3 5 mmol/L(2 cases), no substantial changes in uric acid was found. Conclusion The antihypertensive effects of sustaine d released Indapamide was lasting for 30 hours with slight and tolerable side effects.
出处
《高血压杂志》
CSCD
2003年第6期546-548,共3页
Chinese Journal of Hypertension
